[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641898":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":28,"responsibleParty":38,"collaborators":28,"id":40,"slug":28,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":28,"enrollmentInfo":49,"targetDuration":28,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":28,"overallStatus":58,"whyStopped":28,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":28},{"fullName":5,"class":6},"Verastem, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"VS-7375 Monotherapy 2L\u002F3L","EXPERIMENTAL","2L\u002F3L VS-7375 dose",[13],"Drug: VS-7375",{"label":15,"type":10,"description":16,"interventionNames":17},"VS-7375 Monotherapy 2L\u002F3L Preferred Dose","2L\u002F3L Preferred VS-7375 dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"2L-4L with brain metastasis","2L-4L VS-7375 dose",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","VS-7375","Taken by mouth",[19,9,15],null,[30,35],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Verastem Call Center","CONTACT","7812924204","VS-7375-202TrialSupport@verastem.com",{"name":36,"role":32,"phone":28,"phoneExt":28,"email":37},"Ting Wu, MD","VS-7375-202Medical@verastem.com",{"type":39,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100641898",false,"NCT07659782","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)","TARGET-D 202","Inclusion Criteria:\n\n* Histopathology confirmed unresectable locally advanced or metastatic NSCLC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n* Adequate organ function\n* Received prior treatment with a platinum-based chemotherapy regimen and an immune checkpoint inhibitor in the advanced, non-resectable setting.\n* Have documented disease progression during or following their most recent prior line of therapy.\n\nPatients with 2L\u002F3L on stable or preferred dose:\n\n* Received at least 1 and no more than 2 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.\n\nPatients with 2L-4L with brain metastases:\n\n* Received at least 1 and no more than 3 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.\n* Have asymptomatic and untreated brain metastases\n* At least 1 untreated measurable brain lesion per mRECIST v1.1 with a long axis ≥ 0.5 cm and ≤ 3 cm.\n\nExclusion Criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose\n* History of drug-induced Interstitial Lung Disease\n* Receipt of prior direct RAS inhibitor\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":50,"type":51},105,"ESTIMATED","INTERVENTIONAL",[54],"PHASE2","This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer",[57],"Non-Small Cell Lung Cancer","NOT_YET_RECRUITING","2026-06-15",{"date":61,"type":62},"2026-06-22","ACTUAL",{"date":64,"type":51},"2026-06",{"date":66,"type":51},"2028-12",{"name":5,"class":6}]